The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Asia 2025 | PROCEADE-CRC-01: post-hoc analysis of Precem-TcT in Asian patients
Ken Kato, MD, PhD, National Cancer Center Hospital East, Tokyo, Japan, discusses the efficacy and toxicity of precemtabart tocentecan (Precem-TcT) in the Asian patient population, which was assessed in the PROCEADE-CRC-01 trial (NCT05464030). The results show similar efficacy and toxicity to the Western population, which could allow for global development. Future considerations include adverse events, particularly neutropenia and thrombocytopenia. This interview took place at 2025 European Society for Medical Oncology (ESMO) Asia Congress in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
That shows the similar efficacy for the Asian patient population, that is one of the most important things, and the toxicity is similar to the Western population, Asian population, so I think so the development of this drug will be allowed globally, and so I expect that so far the phase 3 trial compared to the standard of care to the CTC and CTC plus bevacizumab, but we should also take care of the adverse events, mostly with the neutropenia and thrombocytopenia...
That shows the similar efficacy for the Asian patient population, that is one of the most important things, and the toxicity is similar to the Western population, Asian population, so I think so the development of this drug will be allowed globally, and so I expect that so far the phase 3 trial compared to the standard of care to the CTC and CTC plus bevacizumab, but we should also take care of the adverse events, mostly with the neutropenia and thrombocytopenia.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
